Therini Bio
Signal active
Organization
Contact Information
Overview
Therini Bio is a biotechnology company specializing in fibrin-targeting therapies to treat inflammatory neurological and retinal diseases. It develops therapeutics based on unique insights into the novel role of fibrin in driving chronic innate immune activation that characterizes a broad set of human diseases with high unmet needs. The current therapeutic target is based on novel findings by the Akassoglou lab at Gladstone/UCSF that implicate fibrin as a key driver of neuroinflammation.
About
Industries
Biotechnology, Health Care, Medical, Therapeutics
Founded
2016
Employees
1-10
Headquarters locations
San Francisco, California, United States, North America
Social
Profile Resume
Therini Bio headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical, Therapeutics sector. The company focuses on Biotechnology and has secured $4.2B in funding across 64 round(s). With a team of 1-10 employees, Therini Bio is actively contributing to advancements in Biotechnology. Their latest funding round, Grant - Therini Bio, raised $3.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
4
Investors
1
Lead Investors
0
Total Funding Amount
$65.3M
Details
3
Therini Bio has raised a total of $65.3M in funding over 3 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2019 | Seed | 9.3M | ||
| 2021 | Seed | 17.0M | ||
| 2023 | Early Stage Venture | 36.0M |
Investors
Therini Bio is funded by 38 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Therini Bio | - | FUNDING ROUND - Therini Bio | 36.0M |
| Foundation for a Better World | - | FUNDING ROUND - Foundation for a Better World | 36.0M |
| Therini Bio | - | FUNDING ROUND - Therini Bio | 3.0M |
| National Institutes of Health | - | FUNDING ROUND - National Institutes of Health | 3.0M |
Recent Activity
News
May 10, 2024
BioWorld MedTech - Therini Bio's THN-391 shows efficacy in rodent models of ocular diseases
News
Apr 17, 2024
LinkedIn - Therini Bio, Inc. on LinkedIn: A New Therapeutic Target for Traumatic Brain Injury
Funding Round
Apr 27, 2023
Therini Bio raised $36000000 on 2023-04-27 in Series A
Funding Round
Jan 01, 2023
Therini Bio raised $3000000 on 2023-01-01 in Grant
News
Jun 20, 2022
Google Patent - ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN γC DOMAIN AND METHODS OF USE
News
Jun 20, 2022
Google Patent - Antibodies which bind human fibrin or fibrinogen yc domain and methods of use